Vimeo stockholders to receive $7.85 per share in cash Bending Spoons reinforces its commitment to innovation in the video platform market NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Vimeo, Inc.

The Mariposa Center for Safety is focused on reducing abuse. Here's how GOP’s Don Bacon Says Hegseth Blocking Trump on Long-Range Russia Strikes U.S. citizen files claim for $50 million in damages ...

The creation of this content included the use of AI based on templates created, reviewed and edited by journalists in the newsroom. Read more on our AI policy here. A new wildfire was reported today ...

The Italian mobile application developer Bending Spoons S.p.A. today announced its intent to acquire the YouTube rival Vimeo.com Inc. in an all-cash deal worth around $1.38 billion. Bending Spoons ...

Sept 10 (Reuters) - Video platform Vimeo, whose popularity surged during the pandemic, said on Wednesday it will be acquired by Italian app developer Bending Spoons for about $1.38 billion, a deal ...

Vimeo is going private: The video platform, at one time a would-be competitor to YouTube, has agreed to be acquired by European tech company Bending Spoons, in an all-cash deal valued at approximately ...

Vimeo is set to get a new owner. Bending Spoons — the parent of Evernote, WeTransfer, Meetup and fellow video streaming platform Brightcove — plans to take the company into private ownership in an all ...

Video platform Vimeo announced on Wednesday that it has agreed to be acquired by Bending Spoons, one of Europe’s largest mobile app developers, in an all-cash deal valued at approximately $1.38 ...

Video streaming site Vimeo (NASDAQ:VMEO) has entered into a definitive agreement to be acquired by Bending Spoons in an all-cash transaction valued at about $1.38 billion. Under the terms of the ...

Vimeo stockholders to receive $7.85 per share in cash Bending Spoons reinforces its commitment to innovation in the video platform market NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Vimeo, Inc.

The MARIPOSA trial demonstrates that amivantamab plus lazertinib significantly reduces resistance and extends survival in EGFR-mutated NSCLC compared to osimertinib. Dual inhibition of EGFR and MET by ...